title: Home hemodialysis: patient outcomes during a 24-year period of time from 1970 through 1993.
abstract: In the United States, from 1983 to 1993, home hemodialysis use has decreased from 6% to 1.3% of the dialysis population, whereas continuous ambulatory peritoneal dialysis (CAPD) has increased to 20%. Most home hemodialysis programs have withered away because of current patient mix, increase in CAPD, proliferation of outpatient centers, disinterest in nephrologists, and fear of self-cannulation by patients. From 1970 through 1993, 896 patients began dialysis at North Shore and were followed up through 1994. During this period, 687 patients were on in-center hemodialysis, 95 on CAPD, 74 on home hemodialysis, and 40 on in-center peritoneal dialysis. The home hemodialysis patients were younger, with a median age of 44 versus 59 years for in-center hemodialysis patients, and had less comorbidity. The home hemodialysis group had fewer diabetic patients and no renal vascular patients. The 5-year and median survival estimates were significantly better for the home hemodialysis patients versus other dialysis modalities. More home hemodialysis patients received transplants. Compared with the other dialysis modalities, home hemodialysis patients showed significantly improved survival rates. When matched by age, sex, and end-stage renal disease (ESRD) diagnosis to corresponding in-center hemodialysis, the home hemodialysis patients still had significantly better survival rates, but the home hemodialysis patients had less comorbidity. In conclusion, home hemodialysis patients survive longer and have better rehabilitation than other dialysis patients. Reasons for better survival in addition to a younger age and more favorable ESRD diagnosis may include less comorbidity, more patient involvement, and longer dialysis time. Because of these better outcomes, home hemodialysis should be offered to more ESRD patients.
authors.affiliation: Department of Medicine, North Shore University Hospital, Manhasset, NY 11030, USA.
authors.forename: L U
authors.initials: LU
authors.lastname: Mailloux
authors.forename: N
authors.initials: N
authors.lastname: Kapikian
authors.forename: B
authors.initials: B
authors.lastname: Napolitano
authors.forename: R T
authors.initials: RT
authors.lastname: Mossey
authors.forename: A G
authors.initials: AG
authors.lastname: Bellucci
authors.forename: B M
authors.initials: BM
authors.lastname: Wilkes
authors.forename: M A
authors.initials: MA
authors.lastname: Vernace
authors.forename: I J
authors.initials: IJ
authors.lastname: Miller
mesh_terms: D000328:Adult; D017677:Age Distribution; D006437:Hemodialysis, Home; D006801:Humans; D007676:Kidney Failure, Chronic / Q000401:mortality* / Q000628:therapy*; D008875:Middle Aged; D015999:Multivariate Analysis; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States